The potential of 1018 ISS adjuvant in hepatitis B vaccines

Comparative Risk of Liver-Related Mortality From Chronic Hepatitis B Versus Chronic Hepatitis C Virus Infection

(2012) O. Falade-Nwulia et al.   CLINICAL INFECTIOUS DISEASES

Safety and immunogenicity of different two-dose regimens of an investigational hepatitis B vaccine (hepatitis B surface antigen co-administered with an immunostimulatory phosphorothioate oligodeoxyribonucleotide) in healthy young adults

(2012) Scott A. Halperin et al.   VACCINE

Demonstration of safety and enhanced seroprotection against hepatitis B with investigational HBsAg-1018 ISS vaccine compared to a licensed hepatitis B vaccine

(2012) Benjamin P. Sablan et al.   VACCINE

The recombinant globular head domain of the measles virus hemagglutinin protein as a subunit vaccine against measles

(2012) Liubov M. Lobanova et al.   VACCINE

Comparison of safety and immunogenicity of two doses of investigational hepatitis B virus surface antigen co-administered with an immunostimulatory phosphorothioate oligodeoxyribonucleotide and three doses of a licensed hepatitis B vaccine in healthy adults 18–55 years of age

(2012) Scott A. Halperin et al.   VACCINE

Vaccine Adjuvants: Putting Innate Immunity to Work

(2010) Robert L. Coffman et al.   IMMUNITY

Vaccination in the elderly: an immunological perspective

(2009) Wilbur H. Chen et al.   TRENDS IN IMMUNOLOGY

Alum adjuvanticity: Unraveling a century old mystery

(2008) Ennio De Gregorio et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

Persistence of Protection Against Hepatitis B Virus Infection Among Adolescents Vaccinated With Recombinant Hepatitis B Vaccine Beginning at Birth

(2008) Stephanie R. Bialek et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

Molecular and cellular signatures of human vaccine adjuvants

(2008) F. Mosca et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA